Hannover Rueck SE (HVRRY)
OTHER OTC:HVRRY
Top Page
Hannover Rueck SE
(OTC:HVRRY)
Select Model
Select Model
Rating:68Neutral
Price Target:
$58.00
▲(22.70% Upside)
Action:ReiteratedDate:04/12/26
The score is driven mainly by moderately solid underlying financial performance (manageable leverage and strong operating cash flow through 2024) tempered by significant 2025 reporting/inconsistency concerns. Technicals are supportive with price above key moving averages and positive MACD, while valuation adds a positive tilt due to a moderate P/E and a healthy dividend yield.
Positive Factors
Consistent Operating Cash Flow
Multi-year, steady operating cash flow supports durable ability to fund claims, maintain reserves and finance underwriting capacity without excessive external financing. This consistent cash generation underpins capital management, dividend capacity and resilience across insurance cycles.
Negative Factors
2025 Reporting Inconsistencies
Material anomalies in the latest year impede reliable trend analysis and forecasting. For long-term fundamental assessment, unreliable recent figures make it harder to judge true underwriting performance, reserve adequacy and investment returns, raising model and risk-of-error concerns.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Operating Cash Flow
Multi-year, steady operating cash flow supports durable ability to fund claims, maintain reserves and finance underwriting capacity without excessive external financing. This consistent cash generation underpins capital management, dividend capacity and resilience across insurance cycles.
Read all positive factors
Hannover Rueck SE (HVRRY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.58B
Dividend Yield3.57%
Average Volume (3M)1.17K
Price to Earnings (P/E)12.1
Beta (1Y)0.38
Revenue Growth4.35%
EPS Growth12.64%
CountryUS
Employees3,895
SectorFinancial
Sector Strength70
IndustryInsurance - Reinsurance
Share Statistics
EPS (TTM)1.08
Shares Outstanding723,582,800
10 Day Avg. Volume1,549
30 Day Avg. Volume1,170
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)2.48
Price to Sales (P/S)1.34
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.50
Enterprise Value/Gross Profit1.48
Enterprise Value/Ebitda3.78
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)4.41
Revenue Forecast (FY)$32.04B
Hannover Rueck SE Business Overview & Revenue Model
Company Description
Hannover Rück SE, together with its subsidiaries, provides reinsurance products and services worldwide. It operates through Property & Casualty Reinsurance, and Life & Health Reinsurance segments. The company offers property, casualty, facultative...
How the Company Makes Money
Hannover Rueck primarily makes money through (1) underwriting income from reinsurance and (2) investment income on the assets it holds to support reserves and capital.
1) Reinsurance underwriting revenue (core business):
- Premiums: The company e...
Hannover Rueck SE Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong overall performance with substantial growth in net income and increased guidance. While there are strategic realizations of fixed income losses and currency impact challenges, the positive developments in P&C and Life & Health segments, along with a robust investment strategy, signify a strong position for future growth.Positive Updates
Strong Net Income and Increased Guidance
The group net income reached EUR 1.96 billion for the first 9 months, leading to an increase in the full-year guidance to EUR 2.6 billion. This performance reflects strong profitability and favorable currency and tax effects.
Negative Updates
Currency Translation Impact
Negative currency translation effects impacted the shareholders’ equity and OCI, partially offsetting other gains.
Read all updates
Q3-2025 Updates
Positive
Negative
Strong Net Income and Increased Guidance
The group net income reached EUR 1.96 billion for the first 9 months, leading to an increase in the full-year guidance to EUR 2.6 billion. This performance reflects strong profitability and favorable currency and tax effects.
Read all positive updates
Company Guidance
During the earnings call, Hannover Re provided guidance for the financial year 2026, setting a group net income target of at least EUR 2.7 billion, marking a 12.5% increase from the initial guidance for 2025. The company aims for a combined ratio target below 87% for its P&C business, despite anticipated softening rates, and expects a return on investment of around 3.5%. Key metrics include a solvency ratio of 259%, a reinsurance service result target of EUR 925 million for Life & Health, and a projected return on equity of 22%. The company also anticipates mid-single-digit growth in its P&C business, excluding structured reinsurance, and a CSM growth target of around 2%. Additionally, Hannover Re plans to leverage market conditions to improve investment returns by realizing fixed income losses, with a focus on locking in higher interest rates to support future earnings growth.Hannover Rueck SE Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 24.02B | 2.66B | 1.13B | 1.39B | 26.15B |
| Gross Profit | 22.87B | 2.53B | 1.04B | 1.31B | 20.39B |
| EBITDA | 3.41B | 3.37B | 2.01B | 1.44B | 1.85B |
| Net Income | 2.64B | 2.33B | 1.82B | 780.80M | 1.23B |
Balance Sheet | |||||
| Total Assets | 71.30B | 72.13B | 65.67B | 62.96B | 82.90B |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 57.39B | 52.63B | 46.65B | 47.59B |
| Total Debt | 4.14B | 4.67B | 4.88B | 5.51B | 4.37B |
| Total Liabilities | 57.37B | 59.44B | 54.65B | 53.00B | 70.15B |
| Stockholders Equity | 12.92B | 11.79B | 10.13B | 9.06B | 11.89B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | 5.68B | 5.79B | 5.16B | 4.60B |
| Operating Cash Flow | 5.46B | 5.68B | 5.79B | 5.16B | 4.94B |
| Investing Cash Flow | -3.89B | -4.41B | -4.51B | -5.38B | -5.26B |
| Financing Cash Flow | -1.65B | -1.10B | -1.50B | 133.25M | 277.51M |
Hannover Rueck SE Technical Analysis
Positive
47.27
Price Trends
49.66
Positive
49.52
Positive
49.76
Positive
Market Momentum
1.03
Negative
65.72
Neutral
93.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HVRRY, the sentiment is Positive. The current price of 47.27 is below the 20-day moving average (MA) of 51.12, below the 50-day MA of 49.66, and below the 200-day MA of 49.76, indicating a bullish trend. The MACD of 1.03 indicates Negative momentum. The RSI at 65.72 is Neutral, neither overbought nor oversold. The STOCH value of 93.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HVRRY.
Hannover Rueck SE Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $34.15B | 7.15 | 19.02% | ― | 16.68% | -28.54% | |
80 Outperform | $13.18B | 4.70 | 24.24% | 0.57% | -3.96% | -48.08% | |
73 Outperform | $13.44B | 11.38 | 9.48% | 1.76% | 2.10% | 19.23% | |
72 Outperform | $13.32B | 8.83 | 10.61% | 2.37% | 8.62% | -78.92% | |
68 Neutral | $38.58B | 12.14 | 21.53% | 3.57% | 4.35% | 12.64% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
67 Neutral | $41.25B | 15.62 | 7.50% | 2.02% | -23.02% | 52.43% |
* Financial Sector Average
HVRRY
Hannover Rueck SE
53.33
3.22
6.42%
AIG
American International Group
76.87
-2.84
-3.56%
ACGL
Arch Capital Group
95.97
3.10
3.34%
EG
Everest Group
329.87
-14.69
-4.26%
RGA
Reinsurance Group
205.05
27.25
15.33%
RNR
Renaissancere Holdings
303.03
64.70
27.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.